Drug Profile

Eprosartan

Alternative Names: eprosartan mesylate; Navixen; SKB 108566; SKF 108566; Teveten; Teveten SB; Tevetens; Tevetenz

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Class Acrylates; Antihypertensives; Heart failure therapies; Imidazoles; Small molecules; Thiophenes
Mechanism of Action Angiotensin type 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Essential hypertension
Discontinued Heart failure; Renal failure

Most Recent Events

02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
27 Dec 2011 First generic equivalent approved and launched in USA for Essential hypertension
13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com